Curis, Inc. announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option agreement established in January, 2015. As previously reported, the extension of exclusivity is associated with a payment of $7.5 million to Aurigene, payable in two equal installments in the first and third quarters of 2017. The collaboration between Curis and Aurigene is focused on the discovery, development and commercialization of small molecule drug candidates in the fields of immuno-oncology and selected precision oncology targets. Licensed programs within the collaboration include CA-170, a first-in-class oral, small molecule antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints that is currently being studied in a Phase 1 trial in patients with solid tumors and lymphomas; and CA-327, an oral, small molecule immune checkpoint antagonist targeting PD-L1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) and CA-4948, an oral small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), both of which are currently completing IND-enabling studies. The exclusivity extension comes two months after initial data from the CA-170 Ph. 1 Clinical Trial were presented at a scientific meeting – and four months after the companies closed a $24.5 million investment in Curis by Aurigene.